This was a straightforward call. We'd already seen how Astra Zeneca's ultra-rare VITT was handled and that was largely ignored during the ACIP meeting, as if that body of data and response didn't exist. Bayesian priors ignored.
https://www.wired.com/story/pausing-the-jandj-vaccine-was-easy-unpausing-will-be-hard/ … by @jetjocko @WIRED
-
-
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
No reason to block this vaccine, way lesser AE compared with mRNA vaccines.
- Show replies
New conversation -
-
-
I really feel this outrage, living in a country in Europe with severe vaccine shortages. it is so profoundly shortsighted that they didn’t have public health experts—or any dr from underserved rural hospitals for that matter—to remind them of REALITY.
- Show replies
New conversation -
-
-
I am sorry, but in name of safety first, I disagree. Healthy people take these. Please remember your oath.
- Show replies
New conversation -
-
-
Today, a late-stage pancreatic cancer patient drove 27 miles each way to the community clinic where I volunteer. It made me wish we had J&J for him.
-
Is 27 miles the actual distance? That's more or less the exact risk (2 deaths/7 million)
End of conversation
New conversation -
-
-
I’m struggling to understand why they didn’t start with advising the pause for women in the impacted age group?
-
Fundamentally, because we don’t really know if that’s the impacted group, or if the female predominance instead reflects a selection bias (were there more women who got the vaccine?), or chance. The first known case with J&J, during the clinical trial, was a 25-year-old man.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.